Hookipa Pharma Inc. (HOOK)
OTC PINK OTC PINK Primary Summary
Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet
The mean of analysts' price targets for HOOKIPA Pharma (HOOK) points to a 622.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe HOOKIPA Pharma (HOOK) Could Rally 634.38%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 634.4% in HOOKIPA Pharma (HOOK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Will HOOKIPA Pharma Inc. (HOOK) Report Negative Q2 Earnings? What You Should Know
HOOKIPA Pharma (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hookipa Pharma Inc. (HOOK) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Hookipa Pharma Inc. ever had a stock split?
Hookipa Pharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | Malte Peters CEO | OTC PINK Exchange | 43906K209 CUSIP |
| US Country | 82 Employees | - Last Dividend | 10 Jul 2024 Last Split | - IPO Date |
Overview
HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company dedicated to the development of novel immunotherapeutics for the treatment of infectious diseases and cancers. Utilizing its proprietary arenavirus platform, HOOKIPA aims to create effective therapies that can significantly improve patients' lives. Since its establishment in 2011, HOOKIPA has advanced both its research capabilities and its diverse pipeline of product candidates. The company operates out of its headquarters in New York, New York, and engages in strategic collaborations, such as with Gilead Sciences, Inc., to further its research and development efforts. Through its commitment to innovation, HOOKIPA Pharma Inc. strives to address some of the most challenging medical needs in the fields of oncology and infectious diseases.
Products and Services
- HB-200:
- HB-700:
- HB-400:
- HB-500:
- HB-300:
- Collaboration with Gilead Sciences, Inc.:
A leading infectious disease product candidate currently in Phase 2 clinical trials, HB-200 is developed for the treatment of pembrolizumab, showcasing HOOKIPA's dedication to finding innovative solutions for hard-to-treat diseases.
Still in preclinical development, HB-700 targets KRAS mutated cancers, including those affecting the lung, colorectum, and pancreas. This demonstrates HOOKIPA's focus on addressing cancers with high unmet medical needs through its cutting-edge research.
In Phase I clinical trials, HB-400 represents HOOKIPA's efforts to combat Hepatitis B, a disease with significant global impact, showcasing the company's commitment to infectious disease research.
Also in Phase I clinical trials, HB-500 is geared towards the treatment of HIV, further highlighting HOOKIPA's focus on challenging infectious diseases that require new and better therapeutic strategies.
Currently in preclinical stage, the HB-300 program is dedicated to the treatment of prostate cancer. This initiative is part of HOOKIPA's broader cancer research efforts aimed at providing novel therapies for various types of cancer.
This collaboration encompasses preclinical research programs focusing on leveraging HOOKIPA's replicating and non-replicating technology platforms. The objective is to explore potential vaccines and therapies for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus, showcasing HOOKIPA’s capability in forming strategic partnerships to enhance its R&D endeavors.
